TARS News and Press, Tarsus Pharmaceuticals Inc. From 12/15/22

Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a Phase 2a Carpo trial to evaluate the safety, tolerability, and proof-of-activity of TP-05 in healthy subjects TP-05 designed to be an on-demand, long-acting prophy...

Tarsus Pharmaceuticals press release ( NASDAQ: TARS ): Q3 GAAP EPS of -$0.84 misses by $0.12 . As of September 30, 2022, cash, cash equivalents and marketable securities were $226.6M. Cash runway anticipated into at least 2026 for the planned commercial laun...

Tarsus Pharmaceuticals press release ( NASDAQ: TARS ): Q3 GAAP EPS of -$0.84 beats by $0.13 . As of September 30, 2022, cash, cash equivalents and marketable securities were $226.6 million For further details see: Tarsus Pharmaceuticals GAAP EPS of -$0.8...

New Drug Application for TP-03 accepted; PDUFA target action date August 25, 2023 Launched disease education, field medical team and payor engagement in anticipation of TP-03 launch Cash runway anticipated into at least 2026 for the planned commercial launch of TP-03 and...

Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an investigator-initiated trial evaluating meibomian gland atrophy in patients with Demodex blepharitis will also be pre...

Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors Wendy Yarno will become Lead Independent Director and CEO Bobak Azamian will become Chairman upon Dr. Ackermann’s expected transition IRVINE, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) ...

Mr. Morrison brings over 40 years of financial and operational expertise in life sciences IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet patient needs, starting with eye care, through the application...

Demodex blepharitis is a highly prevalent, yet often missed or misdiagnosed lid margin disease that impacts approximately 25 million eye care patients in the U.S. IRVINE, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to fo...

Positive d ata to be presented at WCC VIII and AAO 2022 conferences in Chicago Tarsus recently submitted NDA to the FDA for TP-03 IRVINE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on un...

Tarsus Pharmaceuticals ( NASDAQ: TARS ) submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of TP-03 to treat Demodex blepharitis. Demodex blepharitis is inflammation of the eyelids caused by a type o...